Prevention of Stroke in Atrial Fibrillation After Coronary Stenting

Leonardo Knijnik, Manuel Rivera, Vanessa Blumer, Rhanderson Cardoso, Amanda Fernandes, Gilson Fernandes, Tanira Ferreira, Jose G Romano, Litsa K. Lambrakos, Mauricio G Cohen

Research output: Contribution to journalArticle

Abstract

Background and Purpose- The optimal antithrombotic strategy to balance thromboembolic and bleeding events, especially acute stroke, for patients with atrial fibrillation following coronary stenting remains a matter of debate. We conducted a network meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in atrial fibrillation after coronary stenting. Methods- PubMed, Scopus, and Cochrane Central were searched for randomized controlled trials and observational studies of patients with atrial fibrillation after coronary stenting. The outcomes of interest were stroke, myocardial infarction, major adverse cardiac events, mortality, and major bleeding. A network meta-analysis was performed comparing the available antithrombotic regimens in the literature. Results- Three randomized and 15 observational studies were included, with a total of 23 478 participants. Median follow-up was 2 years. Network meta-analysis demonstrated that vitamin K antagonist plus single antiplatelet therapy or direct-acting oral anticoagulant plus single antiplatelet therapy were the most effective regimens in preventing stroke. Direct-acting oral anticoagulant regimens were associated with lower major bleeding rates than vitamin K antagonist regimens. Regimens with dual antiplatelet therapy were associated with lower rates of myocardial infarction. Vitamin K antagonist plus dual antiplatelet therapy was associated with a lower mortality and low-dose direct-acting oral anticoagulants with decreased major cardiovascular adverse events. Conclusions- Direct-acting oral anticoagulant regimens were associated with less major bleeding and major cardiovascular adverse events, but vitamin K antagonists were associated with decreased mortality and stroke. These results suggest that the decision of antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention needs to be individualized.

Original languageEnglish (US)
Pages (from-to)2125-2132
Number of pages8
JournalStroke
Volume50
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Atrial Fibrillation
Vitamin K
Stroke
Anticoagulants
Hemorrhage
Observational Studies
Mortality
Myocardial Infarction
Therapeutics
Percutaneous Coronary Intervention
PubMed
Randomized Controlled Trials
Network Meta-Analysis

Keywords

  • atrial fibrillation
  • fibrinolytic agents
  • humans
  • percutaneous coronary intervention
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Knijnik, L., Rivera, M., Blumer, V., Cardoso, R., Fernandes, A., Fernandes, G., ... Cohen, M. G. (2019). Prevention of Stroke in Atrial Fibrillation After Coronary Stenting. Stroke, 50(8), 2125-2132. https://doi.org/10.1161/STROKEAHA.119.026078

Prevention of Stroke in Atrial Fibrillation After Coronary Stenting. / Knijnik, Leonardo; Rivera, Manuel; Blumer, Vanessa; Cardoso, Rhanderson; Fernandes, Amanda; Fernandes, Gilson; Ferreira, Tanira; Romano, Jose G; Lambrakos, Litsa K.; Cohen, Mauricio G.

In: Stroke, Vol. 50, No. 8, 01.08.2019, p. 2125-2132.

Research output: Contribution to journalArticle

Knijnik, L, Rivera, M, Blumer, V, Cardoso, R, Fernandes, A, Fernandes, G, Ferreira, T, Romano, JG, Lambrakos, LK & Cohen, MG 2019, 'Prevention of Stroke in Atrial Fibrillation After Coronary Stenting', Stroke, vol. 50, no. 8, pp. 2125-2132. https://doi.org/10.1161/STROKEAHA.119.026078
Knijnik L, Rivera M, Blumer V, Cardoso R, Fernandes A, Fernandes G et al. Prevention of Stroke in Atrial Fibrillation After Coronary Stenting. Stroke. 2019 Aug 1;50(8):2125-2132. https://doi.org/10.1161/STROKEAHA.119.026078
Knijnik, Leonardo ; Rivera, Manuel ; Blumer, Vanessa ; Cardoso, Rhanderson ; Fernandes, Amanda ; Fernandes, Gilson ; Ferreira, Tanira ; Romano, Jose G ; Lambrakos, Litsa K. ; Cohen, Mauricio G. / Prevention of Stroke in Atrial Fibrillation After Coronary Stenting. In: Stroke. 2019 ; Vol. 50, No. 8. pp. 2125-2132.
@article{925f2d2719c94b838c3761af20ad52e8,
title = "Prevention of Stroke in Atrial Fibrillation After Coronary Stenting",
abstract = "Background and Purpose- The optimal antithrombotic strategy to balance thromboembolic and bleeding events, especially acute stroke, for patients with atrial fibrillation following coronary stenting remains a matter of debate. We conducted a network meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in atrial fibrillation after coronary stenting. Methods- PubMed, Scopus, and Cochrane Central were searched for randomized controlled trials and observational studies of patients with atrial fibrillation after coronary stenting. The outcomes of interest were stroke, myocardial infarction, major adverse cardiac events, mortality, and major bleeding. A network meta-analysis was performed comparing the available antithrombotic regimens in the literature. Results- Three randomized and 15 observational studies were included, with a total of 23 478 participants. Median follow-up was 2 years. Network meta-analysis demonstrated that vitamin K antagonist plus single antiplatelet therapy or direct-acting oral anticoagulant plus single antiplatelet therapy were the most effective regimens in preventing stroke. Direct-acting oral anticoagulant regimens were associated with lower major bleeding rates than vitamin K antagonist regimens. Regimens with dual antiplatelet therapy were associated with lower rates of myocardial infarction. Vitamin K antagonist plus dual antiplatelet therapy was associated with a lower mortality and low-dose direct-acting oral anticoagulants with decreased major cardiovascular adverse events. Conclusions- Direct-acting oral anticoagulant regimens were associated with less major bleeding and major cardiovascular adverse events, but vitamin K antagonists were associated with decreased mortality and stroke. These results suggest that the decision of antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention needs to be individualized.",
keywords = "atrial fibrillation, fibrinolytic agents, humans, percutaneous coronary intervention, stroke",
author = "Leonardo Knijnik and Manuel Rivera and Vanessa Blumer and Rhanderson Cardoso and Amanda Fernandes and Gilson Fernandes and Tanira Ferreira and Romano, {Jose G} and Lambrakos, {Litsa K.} and Cohen, {Mauricio G}",
year = "2019",
month = "8",
day = "1",
doi = "10.1161/STROKEAHA.119.026078",
language = "English (US)",
volume = "50",
pages = "2125--2132",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Prevention of Stroke in Atrial Fibrillation After Coronary Stenting

AU - Knijnik, Leonardo

AU - Rivera, Manuel

AU - Blumer, Vanessa

AU - Cardoso, Rhanderson

AU - Fernandes, Amanda

AU - Fernandes, Gilson

AU - Ferreira, Tanira

AU - Romano, Jose G

AU - Lambrakos, Litsa K.

AU - Cohen, Mauricio G

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background and Purpose- The optimal antithrombotic strategy to balance thromboembolic and bleeding events, especially acute stroke, for patients with atrial fibrillation following coronary stenting remains a matter of debate. We conducted a network meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in atrial fibrillation after coronary stenting. Methods- PubMed, Scopus, and Cochrane Central were searched for randomized controlled trials and observational studies of patients with atrial fibrillation after coronary stenting. The outcomes of interest were stroke, myocardial infarction, major adverse cardiac events, mortality, and major bleeding. A network meta-analysis was performed comparing the available antithrombotic regimens in the literature. Results- Three randomized and 15 observational studies were included, with a total of 23 478 participants. Median follow-up was 2 years. Network meta-analysis demonstrated that vitamin K antagonist plus single antiplatelet therapy or direct-acting oral anticoagulant plus single antiplatelet therapy were the most effective regimens in preventing stroke. Direct-acting oral anticoagulant regimens were associated with lower major bleeding rates than vitamin K antagonist regimens. Regimens with dual antiplatelet therapy were associated with lower rates of myocardial infarction. Vitamin K antagonist plus dual antiplatelet therapy was associated with a lower mortality and low-dose direct-acting oral anticoagulants with decreased major cardiovascular adverse events. Conclusions- Direct-acting oral anticoagulant regimens were associated with less major bleeding and major cardiovascular adverse events, but vitamin K antagonists were associated with decreased mortality and stroke. These results suggest that the decision of antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention needs to be individualized.

AB - Background and Purpose- The optimal antithrombotic strategy to balance thromboembolic and bleeding events, especially acute stroke, for patients with atrial fibrillation following coronary stenting remains a matter of debate. We conducted a network meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in atrial fibrillation after coronary stenting. Methods- PubMed, Scopus, and Cochrane Central were searched for randomized controlled trials and observational studies of patients with atrial fibrillation after coronary stenting. The outcomes of interest were stroke, myocardial infarction, major adverse cardiac events, mortality, and major bleeding. A network meta-analysis was performed comparing the available antithrombotic regimens in the literature. Results- Three randomized and 15 observational studies were included, with a total of 23 478 participants. Median follow-up was 2 years. Network meta-analysis demonstrated that vitamin K antagonist plus single antiplatelet therapy or direct-acting oral anticoagulant plus single antiplatelet therapy were the most effective regimens in preventing stroke. Direct-acting oral anticoagulant regimens were associated with lower major bleeding rates than vitamin K antagonist regimens. Regimens with dual antiplatelet therapy were associated with lower rates of myocardial infarction. Vitamin K antagonist plus dual antiplatelet therapy was associated with a lower mortality and low-dose direct-acting oral anticoagulants with decreased major cardiovascular adverse events. Conclusions- Direct-acting oral anticoagulant regimens were associated with less major bleeding and major cardiovascular adverse events, but vitamin K antagonists were associated with decreased mortality and stroke. These results suggest that the decision of antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention needs to be individualized.

KW - atrial fibrillation

KW - fibrinolytic agents

KW - humans

KW - percutaneous coronary intervention

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=85070183091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070183091&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.119.026078

DO - 10.1161/STROKEAHA.119.026078

M3 - Article

C2 - 31303150

AN - SCOPUS:85070183091

VL - 50

SP - 2125

EP - 2132

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 8

ER -